Over the past decade, biomarkers have been recognized as a critical element needed to
improve predictability and efficiency in the process of developing more effective, more …

The FDA, in particular, has written extensively of its vision of the future where imaging
agents of all types will play a pivotal role in speeding up drug development in early clinical …

The Critical Path Initiative (CPI) of the US Food and Drug Administration (FDA), initiated in
2004 and updated with a list of opportunities and guidelines, has 2 key premises:(1) imaging …

The term “biomarker” is increasingly being used with different meanings in the scientific
literature. In some cases it is used to indicate either a molecular probe or a technology or a …

The imaging industry, pharmaceutical companies, the US Food and Drug Administration
(FDA) and other government agencies, and payers all look to imaging as critical to …

The employment of biomarkers (including imaging biomarkers, especially PET) in drug
development has gained increasing attention during recent years. This has been partly …

[en] This article describes the development of nuclear imaging as an enabling technology in
the pharmaceutical industry. Molecular imaging is maturing into an important tool with …

In 2011, new nuclear medicine residency program recommendations included an increased
emphasis on molecular imaging in clinical practice, and the American Board of Nuclear …

Summary The Society of Nuclear Medicine and Molecular Imaging (SNMMI)'s annual
meeting is a premier networking and educational event for the nuclear medicine and …

The process of preclinical drug discovery has changed fundamentally over the past decade,
providing pharmaceutical companies with a large number of novel targets as well as novel …